To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

Inclusion Criteria:

1. The subjects voluntarily joined the study, signed the informed consent, and thecompliance was good;

2. ≥18 years old (calculated by the date of signing the informed consent); Both men andwomen; ECOG score 0~1; Expected survival ≥3 months;

3. Patients with stage IIA-IIIA NSCLC who had previously received PD-1/PD-L1 inhibitorscombined with chemotherapy neoadjuvant therapy and underwent R0 resection forcurative purposes before surgery (note: the disease was presented in the AmericanJoint Committee on Cancer (AJCC)/Union International Against Cancer (UICC) 8thedition of lung cancer TNM staging);

4. For patients who did not achieve pathological complete response after PD-1/PD-L1inhibitor combined with chemotherapy neoadjuvant treatment, and the time between thefirst trial medication after surgery was required to be 4-12 weeks;

5. The main organs function well and meet the standards;

6. Women of reproductive age should agree that effective contraception must be usedduring the study period and for 6 months after the end of the study, and that serumor urine pregnancy tests are negative within 7 days prior to study enrollment; Menshould agree that effective birth control must be used during the study period andfor 6 months after the end of the study period.

Exclusion Criteria:

1. Have had or are currently suffering from other malignant tumors within 5 years. Thefollowing two conditions can be included: other malignancies treated with a singleoperation, achieving continuous 5-year disease-free survival (DFS); Cured cervicalcarcinoma in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (cancer in situ) and T1 (tumor infiltrating basalmembrane)];

2. Subjects are known to have genetic abnormalities that have been approved fortargeted drug therapy (non-squamous cell carcinoma subjects are required to haveEGFR or ALK gene tested or provide previous test reports during the screeningperiod)

3. Cardiovascular and cerebrovascular abnormalities:

4. Patients with past or existing heart failure, degree II or higher heart block;

5. Past or present myocardial infarction or unstable angina pectoris, clinicallysignificant supraventricular or ventricular arrhythmias requiring treatment orintervention;

6. Occurrence of arteriovenous thrombosis/cancer embolus events within 6 months,such as cerebrovascular accident (including transient ischemic attack, cerebralhemorrhage, cerebral infarction requiring clear diagnosis), vascular embolism (including deep vein thrombosis, arterial thrombosis, pulmonary embolism,etc.);

7. Participated in other drug clinical trials within the past 30 days;

8. Within 2 weeks before starting the administration, it has been treated with Chinesepatent medicines (including compound Cantharides capsule, Kangai injection,Kanglaite capsule/injection, Aidi injection, Bruceae oil injection/capsule,Xiaoaipingtablet/injection, hualbufatin capsule, etc.) with anti-tumor indicationsspecified in the NMPA approved drug instructions;

9. Received major surgery other than radical resection of lung cancer within 4 weeksprior to initiation of administration; According to the investigator, the patientwas not eligible to participate in this clinical study for other reasons.